|
|
代偿期乙肝肝硬化抗病毒治疗的研究进展
|
Abstract:
慢性乙型肝炎病毒(hepatitis B virus, HBV)感染是肝硬化及肝癌发生的主要病因。疾病进展与体内HBV DNA水平息息相关，抗病毒治疗能够有效抑制病毒复制，减缓肝硬化失代偿、肝细胞癌及死亡的发生，延长患者生存时间，提高患者生存质量。本文主要介绍了适合代偿期乙肝肝硬化抗病毒治疗的药物，突出各指南对代偿期乙肝肝硬化的推荐意见。
Chronic hepatitis B virus (HBV) infection is the main cause of liver cirrhosis and liver cancer. Disease progression is closely related to the level of HBV DNA in the body, and antiviral therapy can effectively inhibit viral replication, slow down the occurrence of cirrhosis loss of compensation, hepatocellular carcinoma and death, prolong the survival time of the patients, and improve the quality of their survival. This article focuses on the drugs suitable for antiviral therapy for compensated hepatitis B cirrhosis, highlighting the recommendations of various guidelines for compensated hepatitis B cirrhosis.
| [1] | Schweitzer, A., Horn, J., Mikolajczyk, R.T., et al. (2015) Estimations of Worldwide Prevalence of Chronic Hepatitis B Virus Infection: A Systematic Review of Data Published between 1965 and 2013. The Lancet, 386, 1546-1555. https://doi.org/10.1016/S0140-6736(15)61412-X |
| [2] | Ott, J.J., Stevens, G.A., Groeger, J., et al. (2012) Global Epidemiology of Hepatitis B Virus Infection: New Estimates of Age-Specific HBsAg Seroprevalence and Endemicity. Vaccine, 30, 2212-2219. https://doi.org/10.1016/j.vaccine.2011.12.116 |
| [3] | WHO (2015) Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. WHO, Geneva. |
| [4] | 谷雷雷, 张欣欣. 乙型肝炎肝硬化患者的抗病毒治疗[J]. 上海交通大学学报(医学版), 2015, 35(11): 1717-1721. |
| [5] | Lozano, R., Naghavi, M., Foreman, K., et al. (2012) Global and Regional Mortality from 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010. The Lancet, 380, 2095-2128. |
| [6] | Goldstein, S.T., Zhou, F., Hadler, S.C., et al. (2005) A Mathematical Model to Estimate Global Hepatitis B Disease Burden and Vaccination Impact. International Journal of Epidemiology, 34, 1329-1339. https://doi.org/10.1093/ije/dyi206 |
| [7] | Wang, F.S., Fan, J.G., Zhang, Z., et al. (2014) The Global Burden of Liver Disease: The Major Impact of China. Hepatology, 60, 2099-2108. https://doi.org/10.1002/hep.27406 |
| [8] | Liaw, Y.F. (2013) Reversal of Cirrhosis: An Achievable Goal of Hepatitis B Antiviral Therapy. Journal of Hepatology, 59, 880-881. https://doi.org/10.1016/j.jhep.2013.05.007 |
| [9] | Li, C.Z., Cheng, L.F., Li, Q.S., et al. (2013) Antiviral Therapy Delays Esophageal Variceal Bleeding in Hepatitis B Virus-Related Cirrhosis. World Journal of Gastroenterology, 19, 6849-6856. https://doi.org/10.3748/wjg.v19.i40.6849 |
| [10] | 林勇, 曾欣, 胡平方. 中国肝硬化临床诊治共识意见[J]. 临床肝胆病杂志, 2023, 39(9): 2057-2073. |
| [11] | 慢性乙型肝炎防治指南(2010年版) [J]. 实用肝脏病杂志, 2011, 14(2): 81-89. |
| [12] | European Association for the Study of the Liver (2012) EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B Virus Infection. Journal of Hepatology, 57, 167-185. https://doi.org/10.1016/j.jhep.2012.02.010 |
| [13] | Liaw, Y.F., Kao, J.H., Piratvisuth, T., et al. (2012) Asian-Pacific Consensus Statement on the Management of Chronic Hepatitis B: A 2012 Update. Hepatology International, 6, 531-561. https://doi.org/10.1007/s12072-012-9365-4 |
| [14] | Terrault, N.A., Bzowej, N.H., Chang, K.M., et al. (2016) AASLD Guidelines for Treatment of Chronic Hepatitis B. Hepatology, 63, 261-283. https://doi.org/10.1002/hep.28156 |
| [15] | 王贵强, 王福生, 成军, 等. 慢性乙型肝炎防治指南(2015年版) [J]. 实用肝脏病杂志, 2016, 19(3): 389-400. |
| [16] | European Association for the Study of the Liver (2017) European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. Journal of Hepatology, 67, 370-398. |
| [17] | 王贵强, 王福生, 庄辉, 等. 慢性乙型肝炎防治指南(2019年版) [J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. |
| [18] | Alshuwaykh, O., Daugherty, T., Cheung, A., et al. (2022) Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection in Those Not Meeting Criteria for Antiviral Therapy. Hepatology Communications, 6, 3052-3061. https://doi.org/10.1002/hep4.2064 |
| [19] | 尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版) [J]. 实用肝脏病杂志, 2023, 26(3): 457-478. |
| [20] | 杨雯. 恩替卡韦对乙肝肝硬化患者肝纤维化的影响研究[J]. 甘肃科技, 2022, 38(6): 110-112 115. |
| [21] | 陈娟娟, 张瑞, 陈保站, 等. 恩替卡韦治疗对乙肝肝硬化患者肝功能及肝硬化指标的影响[J]. 中国医院药学杂志, 2018, 38(14): 1526-1529 1557. https://doi.org/10.13286/j.cnkichinhosppharmacyj.2018.14.18 |
| [22] | Croagh, C.M. and Lubel, J.S. (2014) Natural History of Chronic Hepatitis B: Phases in a Complex Relationship. World Journal of Gastroenterology, 20, 10395-10404. https://doi.org/10.3748/wjg.v20.i30.10395 |
| [23] | 刘华梅, 张鑫. 恩替卡韦与富马酸替诺福韦二吡呋酯抗病毒治疗对乙型肝炎肝硬化代偿期患者的临床效果[J]. 中外医学研究, 2020, 18(7): 11-13. https://doi.org/10.14033/j.cnki.cfmr.2020.07.005 |
| [24] | 高沿航. 恩替卡韦与替诺福韦治疗的慢性乙型肝炎患者发生肝细胞癌的风险: 一项韩国全国性队列研究[J]. 临床肝胆病杂志, 2018, 34(12): 2664. |
| [25] | Huang, Y.H., Shen, C.W., Chen, C.Y., et al. (2023) Comparative Effectiveness of Tenofovir versus Entecavir in Patients with Hepatitis B Virus-Related Cirrhosis in Taiwan: A Retrospective Cohort Study. Frontiers in Pharmacology, 14, Article ID: 1301120. https://doi.org/10.3389/fphar.2023.1301120 |
| [26] | Huang, Y., Chen, L., Huang, R., Zhu, C., Shang, J., Qian, Y., Lian, J., Liu, L., Jiang, J., Liu, C., Gui, H. and Xie, Q. (2022) Tenofovir Is Superior to Entecavir in Reducing HCC for Patients with HBV-Related Compensated Cirrhosis at High HCC Risk Scores. Therapeutic Advances in Chronic Disease, 13. https://doi.org/10.1177/20406223221102791 |
| [27] | Zhang, P., Liu, Q., Yuan, M., et al. (2018) Tenofovir Disoproxil Fumarate Reduce Incidence of HCC Development in CHB-Patients with Compensated Cirrhosis. Infectious Agents and Cancer, 13, Article No. 30. https://doi.org/10.1186/s13027-018-0203-8 |
| [28] | 王方, 王妮娜, 魏嘉, 等. 替诺福韦酯经治慢性乙型肝炎和乙型肝炎肝硬化患者血清免疫球蛋白和补体水平的变化[J]. 中国肝脏病杂志: 电子版, 2018, 10(4): 96-100. |
| [29] | 戚敬虎, 鞠金昌, 徐雷, 等. 富马酸替诺福韦二吡呋酯单药治疗拉米夫定耐药慢性乙型肝炎的疗效观察[J]. 中华肝脏病杂志, 2016, 24(4): 307-309. |
| [30] | 赵庆英, 杨瑞虹. 富马酸丙酚替诺福韦与富马酸替诺福韦二吡呋酯治疗慢性乙型肝炎患者疗效与安全性比较[J]. 系统医学, 2021, 6(11): 39-41. https://doi.org/10.19368/j.cnki.2096-1782.2021.11.039 |
| [31] | 李俊利, 赵丹, 程留奇, 等. 富马酸丙酚替诺福韦对高病毒载量乙肝肝硬化代偿期患者抗病毒疗效、肝功能及肝纤维化血清学指标的影响分析[J]. 航空航天医学杂志, 2023, 34(10): 1222-1224 1233. |
| [32] | 宋玉文, 陈立震, 金文文, 等. 富马酸丙酚替诺福韦治疗青岛地区60岁及以上慢性乙型肝炎患者的有效性和安全性[J]. 临床肝胆病杂志, 2023, 39(5): 1061-1069. |
| [33] | 卢嘉惠, 张丛楠, 何鹏园, 等. 富马酸丙酚替诺福韦治疗慢性乙型肝炎合并脂肪肝的疗效及安全性[J]. 肝脏, 2022, 27(8): 858-862 867. https://doi.org/10.14000/j.cnki.issn.1008-1704.2022.08.012 |
| [34] | Liu, Z., Jin, Q., Zhang, Y., et al. (2021) Randomised Clinical Trial: 48 Weeks of Treatment with Tenofovir Amibufenamide versus Tenofovir Disoproxil Fumarate for Patients with Chronic Hepatitis B. Alimentary Pharmacology & Therapeutics, 54, 1134-1149. https://doi.org/10.1111/apt.16611 |
| [35] | Li, L., Zhou, J., Li, Y., et al. (2023) Effectiveness and Safety of Tenofovir Amibufenamide and Its Comparison with Tenofovir Alafenamide in Patients with Chronic Hepatitis B: Results from a Retrospective Real-World Study. Frontiers in Pharmacology, 14, Article ID: 1165990. https://doi.org/10.3389/fphar.2023.1165990 |
| [36] | Pestka, S., Langer, J.A., Zoon, K.C., et al. (1987) Interferons and Their Actions. Annual Review of Biochemistry, 56, 727-777. https://doi.org/10.1146/annurev.bi.56.070187.003455 |
| [37] | Jonasch, E. and Haluska, F.G. (2001) Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities. Oncologist, 6, 34-55. https://doi.org/10.1634/theoncologist.6-1-34 |
| [38] | Kusano, H., Akiba, J., Ogasawara, S., et al. (2013) Pegylated Interferon-α2a Inhibits Proliferation of Human Liver Cancer Cells in Vitro and in Vivo. PLOS ONE, 8, e83195. https://doi.org/10.1371/journal.pone.0083195 |
| [39] | Jindal, A., Vyas, A.K., Kumar, D., et al. (2018) Higher Efficacy of Pegylated Interferon-α2b Add-On Therapy in Hepatitis B Envelope Antigen-Positive Chronic Hepatitis B Patients on Tenofovir Monotherapy. Hepatology Research, 48, 451-458. https://doi.org/10.1111/hepr.13049 |
| [40] | 张瑜, 路青华, 曹海芳, 等. 恩替卡韦联合干扰素治疗乙肝肝硬化的临床效果及对肝纤维化和细胞免疫功能的影响[J]. 中国现代医生, 2021, 59(23): 83-86. |
